Author:
Höglinger Günter,Seifert Roland
Publisher
Springer Berlin Heidelberg
Reference25 articles.
1. Antonini A, Jost WH (2018) Intrajejunale Levodopa- und Apomorphin-Infusion zur Therapie motorischer Komplikationen bei fortgeschrittener Parkinson-Krankheit. Fortschr Neurol Psychiatr 86:55–59
2. de Bie RMA, Clarke CE, Espay AJ, Fox SH, Lang AE (2020) Initiation of pharmacological therapy in Parkinson’s disease: when, why, and how. Lancet Neurol 19:452–461
3. Binde CD, Tvete IF, Gåsemyr JI, Natvig B, Klemp M (2020) Comparative effectiveness of dopamine agonists and monoamine oxidase type-B inhibitors for Parkinson’s disease: a multiple treatment comparison meta-analysis. Eur J Clin Pharmacol 76(12):1731–1743
4. Birkmayer W, Hornykiewicz O (1961) Der L-Dioxyphenylalanin (L-DOPA) Effekt bei der Parkinson-Akinese. Wien Klin Wschr 78:787–788
5. Canadian Agency for Drugs and Technologies in Health (2015) CADTH final recommendation: Rotigotine – resubmission. https://www.cadth.ca/rotigotine-7